Effect of severe renal impairment on the pharmacokinetics of brigatinib

Conclusions These findings support a brigatinib dosage reduction of approximately 50 % in patients with severe renal impairment.Trial registry: Not applicable.

http://link.springer.com/10.1007/s10637-021-01095-5

Source: Investigational New Drugs - September 9, 2021 Category: Drugs & Pharmacology Source Type: research